Future studies are required to determine if low FSHR enables the heteromer formation with other membrane G protein-coupled receptors and lead to enhanced proliferation in ovarian cancer cells via β-arrestins dependent pathways. The gene discussed is FSHR; the disease is ovarian carcinoma.